Abstract:Background & aims: Previous research established that the availability of L-arginine affects placental vascular development and fetal growth. However, practical details associated with the effects of L-arginine supplementation on the neonatal outcomes of hypertensive disorder (HD) and intrauterine growth restriction (IUGR) pregnancies are limited. Methods: The PubMed, ScienceDirect, and Web of Science databases were searched for peer-reviewed literature published by September 30, 2021 to investigate the operational details of L-arginine supplementation in improving neonatal outcomes in complicated pregnancies. Standardized mean difference (SMD) and weighted mean difference (WMD) of continuous variables, as well as the risk ratio (RR) for categorical variables were pooled by random-effects models. Results: The results indicated that L-arginine supplementation increased the plasma nitric oxide (NO) concentrations in IUGR pregnancies (SMD: 0.71; 95% CI: 0.45, 0.97; I-2 = 0%), but decreased the risk of preeclampsia in HD mothers (RR: 0.49; 95% CI: 0.31, 0.76; I-2 = 0%). Administration with L-arginine elevated birth weights both in hypertensive and IUGR pregnant women, with WMDs of 194.70 g (95% CI: 58.21, 331.20; I-2 = 44.2%) and 134.00 g (95% CI: 43.53, 224.46; I-2 = 42.4%), respectively. However, the intervention had no effect on gestational age except in HD pregnancies (WMD: 7.05 d; 95% CI: 3.16, 10.95; I-2 = 36.5%). L-arginine administration during pregnancy significantly reduced the small for gestational age (SGA) risk of fetus both in HD (RR: 0.51; 95% CI: 0.31, 0.83; I-2 = 0.0%) and IUGR mothers (RR: 0.46; 95% CI: 0.25, 0.88; I-2 = 0.0%). Subgroup analyses revealed that L-arginine supplementation at <4 g/ d dosage or for >1-month duration or in the third trimester had a greater effect on birth weights in HD women without proteinuria, but a higher L-arginine dosage was more beneficial for extending gestational age and reducing the risk of SGA in older pregnancies. Additionally, intravenous infusion of L-arginine, but not oral administration, significantly increased birth weight in IUGR pregnancies with elevated NO concentrations, although the recommended amount should be confined to <4 g/d. Conclusions: These findings provide practical guidelines for L-arginine supplementation to improve the birth outcomes of complicated pregnancies. Registry number: CRD42021246290 (https://www.crd.york.ac.uk/PROSPERO). (C) 2022 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

The components of arginine and methylarginine metabolism are indicative of altered kidney function in intrauterine growth-restricted neonates

Comparison of Diagnostic Values of Maternal Arginine Concentration for Different Pregnancy Complications: A Systematic Review and Meta-Analysis

L-arginine supplementation improved neonatal outcomes in pregnancies with hypertensive disorder or intrauterine growth restriction: A systematic review and meta-analysis of randomized controlled trials

Epigenetic Changes in Peripheral Leucocytes As Biomarkers in Intrauterine Growth Retardation Rat

Arginine bioavailability and endothelin-1 system in the regulation of vascular function of umbilical vein endothelial cells from intrauterine growth restricted newborns.

Assessment of the arginine and glutamic acid content in the blood serum of full-term newborns with intrauterine growth retardation

Serum and urinary biomarkers to predict acute kidney injury in premature infants: a systematic review and meta-analysis of diagnostic accuracy

A Comparative Proteomic Study of Nephrogenesis in Intrauterine Growth Restriction

Metabolic Biomarkers of Monochorionic Twins Complicated with Selective Intrauterine Growth Restriction in Cord Plasma and Placental Tissue

Urine interleukin-18 and cystatin-C as biomarkers of acute kidney injury in critically ill neonates

Urinary Nerve Growth Factor in full-term, preterm and intra uterine growth restriction neonates: Association with brain growth at 30-40 days of postnatal period and with neuro-development outcome at two years. A pilot study

Biomarkers in neonates receiving potential nephrotoxic drugs

Early Urinary Angiotensinogen Excretion in Critically Ill Neonates.

Effect of L-arginine on nitric oxide levels of maternal and neonatal umbilical blood in intrauterine growth retardation

[A Preliminary Study of Renal Function in Small-for-gestational-age Infants at Early Stage after Birth].

N-Carbamylglutamate and l-Arginine Promote Intestinal Absorption of Amino Acids by Regulating the mTOR Signaling Pathway and Amino Acid and Peptide Transporters in Suckling Lambs with Intrauterine Growth Restriction

In Vivo Detection of Perinatal Brain Metabolite Changes in a Rabbit Model of Intrauterine Growth Restriction (IUGR)

Early prediction of acute kidney injury in neonates with cardiac surgery

Urine Biomarkers for the Assessment of Acute Kidney Injury in Neonates with Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia

A novel urinary biomarker profile to identify acute kidney injury (AKI) in critically ill neonates: a pilot study

Preliminary analysis of metabonomics in selective intrauterine growth restriction with abnormal umbilical artery Doppler flow